print small

Participating Countries:

Algeria

Argentina

Australia

Austria

Belgium

Bosnia and Herzegovina

Bulgaria

Croatia

Czech Republic

Denmark

Finland

France

FYR of Macedonia

Germany

Greece

Iceland

Ireland

Israel

Italy

Lithuania

Morocco

Netherlands

New Zealand

Poland

Portugal

Romania

Russian Federation

Serbia

Slovenia

Spain

Sweden

Switzerland

Turkey

Ukraine

United Kingdom

United States

Member area provided by LTFE
COST is supported by the EU Framework Programme Horizon 2020
This website is supported by COST
26/01/2016 (Added to site)
Author(s): Bianchi, G.; Campanacci, L.; Rimondi, E.; Ruggieri, P.

Palliative treatments: electrochemotherapy and thermoablation

Book: Advances in Bone Metastasis Management, (2012), pp. 114-122
DOI: 10.2217/ebo.11.362
Request reprint  |  Tell your friend  | 

Abstract: Metastatic disease is a major cause of pain and decreased quality of life in patients with cancer. Autopsy studies have shown that up to 85% of patients who die from breast, prostate or lung cancer have histological evidence of bone metastases at the time of death. In Europe, the number of new cases of bone metastases per year is approximately 1 in 100,000. Worsening of patients’ quality of life is due to associated symptoms such as intractable pain, pathological fractures, spinal cord compression, hypercalcemia and reduction of movement and performance status.



Project Office

Working groups

Steering Committee

Founding members

DC Rapporteurs

Related sites: